ASH 2023 | Secondary-type mutations do not impact the favorable prognosis in NPM1-mutated AML
Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, presents a retrospective analysis exploring the impact of secondary-type mutations on the favorable prognosis linked to NPM1 mutations in acute myeloid leukemia (AML). The study indicates that the prognosis remains comparable between patients with both NPM1 and secondary-type mutations and those with only NPM1 mutations. These findings suggest that secondary-type mutations do not diminish the positive prognosis associated with NPM1 mutations in AML. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Pfizer, Novartis, Janssen, BMS, Astellas, AbbVie, Servier
Honoraria: Pfizer, Novartis, Janssen, BMS, Astellas, AbbVie, Servier
Research Funding: Pfizer, Novartis, AbbVie
